Comparative Pharmacology
Head-to-head clinical analysis: AZATHIOPRINE SODIUM versus ZORTRESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZATHIOPRINE SODIUM versus ZORTRESS.
AZATHIOPRINE SODIUM vs ZORTRESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azathioprine is a prodrug of 6-mercaptopurine. It inhibits purine synthesis by interfering with the synthesis of DNA, RNA, and cellular proteins, thereby suppressing immune responses.
Inhibits mammalian target of rapamycin (mTOR) by binding to FKBP-12, blocking cell cycle progression from G1 to S phase, thereby suppressing cytokine-driven T-cell proliferation.
1-2 mg/kg/day IV or oral, initially; maintenance 0.5-1 mg/kg/day IV or oral. For severe organ rejection: 3-5 mg/kg/day IV.
1.5 mg orally twice daily, administered with cyclosporine and corticosteroids.
None Documented
None Documented
Terminal elimination half-life of azathioprine is approximately 3-5 hours; its active metabolite 6-mercaptopurine has a half-life of 0.5-1.5 hours. However, the pharmacodynamic effect (immunosuppression) persists longer due to intracellular accumulation of thioguanine nucleotides.
Terminal elimination half-life is approximately 10-15 hours in renal transplant patients. In de novo liver transplant patients, half-life is ~13 hours. The effective half-life supports twice-daily dosing.
Primarily renal: approximately 50% as unchanged drug and metabolites (6-mercaptopurine, thiouric acid) within 24 hours. Biliary/fecal excretion accounts for minor fraction (<5%).
Primarily fecal (~78%) with <2.5% excreted unchanged in urine. Small amount via biliary elimination.
Category D/X
Category C
Immunosuppressant
Immunosuppressant